China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

SSZSE:300294
13.25
CNY
-0.04
(-0.30%)
-0.34EPS
7.53BMarket Cap
Mar 22Next Earn
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A
SZSE:300294
(Shenzhen Stock Exchange)

Recent

price

13.25

P/E

ratio

- -

div

yld

0.56%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.55
0.77
0.71
0.72
1.29
1.57
3.55
3.65
5.65
6.48
5.89
6.08
5.49
5.25
3.45
4.02
2.84
Revenue per Share
0.2
0.26
0.24
0.24
0.31
0.44
1.02
0.89
1.11
1
0.61
0.79
0.86
0.47
0.79
0.22
-0.33
Basic EPS, GAAP
-0.05
0.25
0.21
0.17
0.22
-0.04
-0.38
-0.65
-0.19
-0.48
1.35
2.93
0.91
1.1
0.2
-0.93
- -
Free Cash Flow per Basic Share
0.09
0.01
0.06
0.11
0.11
0.14
0.21
0.1
0.24
0.22
0.23
0.11
0.17
0.27
0.46
0.31
0.07
Dividend per Share
0.77
1.03
2.2
2.32
2.52
4.67
5.22
6.05
8.55
9.03
9.48
13.35
14.25
14.52
14.85
14.75
14.77
Book Value per Share
0.72
0.98
2.17
1.85
2.05
3.17
3.7
4
6.47
6.85
7.22
11.52
12.24
13.73
11.66
12.3
12.46
Tangible Book Value per Share
256
255
319
340
340
345
267
401
423
426
426
436
503
505
503
512
504
Basic Weighted Avg Shares
142
197
227
245
438
543
947
1,461
2,388
2,761
2,513
2,651
2,759
2,652
1,735
2,059
1,432
Sales/Revenue/Turnover
41.11
37.94
31.29
31.31
28.51
29.79
33.43
28.42
24.14
19.53
12.79
17.62
18.81
20.96
26.8
16.61
5.08
Operating Margin (%)
17
17
18
19
27
30
44
46
55
83
83
99
97
99
103
152
- -
Depreciation Expense
50
65
75
82
104
152
272
357
469
426
260
345
432
237
397
113
-168
Net Income, GAAP
15.69
15.1
15.24
15.75
15.23
15.46
15.42
15.25
15.23
14.98
16.11
19.15
16.26
29.84
16.99
- -
- -
Effective Tax Rate (%)
35.24
33.16
33.07
33.6
23.8
27.95
28.74
24.42
19.65
15.43
10.35
13
15.67
8.95
22.88
5.47
-11.73
Profit Margin (%)
90
155
598
468
516
831
761
1,038
2,240
2,096
2,051
5,015
5,368
5,971
4,308
4,200
4,375
Working Capital
40
40
- -
- -
- -
22
22
450
450
269
60
33
10
24
7
60
68
LT Debt
197
263
752
847
924
1,908
2,132
2,484
3,771
3,989
4,192
6,920
7,285
7,321
7,488
7,439
7,450
Total Equity
16.67
20.93
13.17
9.83
12.25
11.21
13.23
13.84
12.83
9.73
6.11
6.22
6.22
3.39
5.33
- -
- -
Return on Invested Capital (%)
20.89
24.12
14.43
10.32
10.54
9.56
12.99
13.53
12.82
9.71
5.75
5.91
5.88
3.1
5.36
- -
- -
Return on Capital (%)
27.62
28.36
14.82
10.68
12.62
11.11
13.71
15.78
15.31
11.19
6.49
6.3
6.17
3.27
5.36
1.51
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
6
6
LT Borrowings
58
58
58
LT Finance Leases
11
10
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
504
504
504
Market Capitalization
9,359
7,181
7,533

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,954
5,012
5,037
Cash, Cash Equivalents & STI
2,768
2,772
2,786
Accounts Receivable, Net
797
783
641
Inventories
1,029
1,021
1,114
Total Current Liabilities
785
699
662
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.34%
14.49%
-0.65%
Free Cash Flow
1.41%
-113.59%
-564.91%
Net Income, GAAP
10.22%
1.69%
-71.61%
Sales/Revenue/Turnover
18.85%
-2.04%
18.69%
Total Cash Common Dividend
27.09%
26.05%
-32.71%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
448
447
349
490
1,735
2025
536
472
- -
585
2,059
2026
321
322
203
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
0.33
0.19
-0.03
0.79
2025
0.28
0.17
- -
-0.46
0.22
2026
0.06
0.04
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.16
0.46
2025
- -
- -
- -
- -
0.31
2026
- -
0.07
- -
- -
- -
Business
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) engages in the research, development, production, and sale of blood products and related pharmaceuticals in China. The company offers a comprehensive portfolio of blood products including human blood albumin, human immunoglobulins such as intravenous human immunoglobulin and hepatitis B human immunoglobulin, rabies immunoglobulin, coagulation factors like human fibrinogen, and freeze-dried intravenous human immunoglobulin; biochemical drugs such as bone polypeptide, oxytocin, and heparin sodium; chemical medicines including diabetes treatments like metformin hydrochloride enteric-coated tablets, glimepiride tablets, pioglitazone hydrochloride dispersible tablets, and calcium dobesilate capsules, as well as anti-infective, cardiovascular, and cerebrovascular drugs; and active pharmaceutical ingredients. Founded in 1993 and headquartered in Fuzhou, Jiangxi Province, the company operates primarily in China through production bases, single plasma collection stations, and a network of member enterprises, serving medical and health markets as a key platform under China Resources Health Division. Recent developments include its restructuring and full integration into China Resources Pharmaceutical Group, solidifying its position in the biopharmaceutical sector; board appointments approved in 2025 to strengthen governance; and involvement in provincial key R&D projects in Jiangxi, alongside operational enhancements such as updates to product information disclosures for human albumin injections and procurement for plasma stations.